Veritas In Silico
Veritas In Silico is a start-up to research and sales of pharmaceuticals.
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor | €0.0 | round | |
| investor investor investor investor | €0.0 | round | |
N/A | Series C | ||
| Total Funding | 000k | ||
Related Content
Veritas In Silico, a Japanese biotechnology firm founded in November 2016 by Dr. Shingo Nakamura, is focused on the discovery of drugs that target messenger RNA (mRNA). The company’s core technology was developed by CEO Shingo Nakamura to overcome previous difficulties in identifying target structures for mRNA. Veritas In Silico went public on the Growth Market of the Tokyo Stock Exchange on February 8, 2024.
The company operates a platform business centered on its proprietary ibVIS® technology, which integrates computational (in silico) analysis with experimental biology to identify druggable structural motifs on mRNA. This platform facilitates the discovery of both small molecule drugs and antisense oligonucleotide (ASO) therapeutics. A key feature of the ibVIS platform is its ability to be integrated with the existing drug discovery infrastructure of partner companies, including their chemical libraries. Veritas In Silico's business model involves collaborative research and licensing agreements with pharmaceutical companies. Through these partnerships, the company engages in multi-year drug discovery research, covering processes from target identification and screening to the nomination of drug candidates. Partners may obtain exclusive worldwide rights to develop and market the compounds discovered through the collaboration.
The company's primary clients are pharmaceutical firms, including notable collaborators like Takeda, Shionogi, RaQualia Pharma, and Mitsubishi Gas Chemical. Revenue is generated through these collaborations. Looking ahead, Veritas In Silico plans to transition to a hybrid business model in 2025, which will involve developing its own in-house drug pipelines alongside its platform business, with the long-term goal of becoming a specialty pharmaceutical company.
Keywords: mRNA-targeted drugs, drug discovery platform, small molecule drugs, antisense oligonucleotide, in silico analysis, computational biology, RNA structural analysis, biotechnology, pharmaceutical partnerships, ibVIS platform, nucleic acid drugs, therapeutics, drug development, preclinical research, life sciences, HealthTech, Shingo Nakamura, Tokyo Stock Exchange, joint research, licensing agreements